New serums take on hydroquinone in skin brightening showdown
NCT ID NCT07644871
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This 4-week pilot study tested two brightening serums against 4% hydroquinone in 18 adults with hyperpigmentation or melasma. Each participant used different products on each side of their face to compare results. The goal was to see if the serums could improve skin tone evenness and reduce dark spots.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- brightening serums (cosmetics) and 4% hydroquinone
- What this could lead to
- If successful, these serums could offer a gentler alternative to hydroquinone for evening skin tone and reducing dark spots.
- What could go wrong
- This is a very small, short pilot study with only 18 participants, so results may not apply widely. Cosmetics are less regulated than drugs, and effectiveness may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
18 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * In good general health (physical, mental, and social well-being, not merely the absence of disease/infirmity), according to subject self-report. * Having Fitzpatrick skin type I-VI (refer to Appendix I: Fitzpatrick Skin Type) * Age 20 to 60 years. * Subjects with self-perceived hyperpigmented facial skin * Having mild to severe (score of 3-9 according to a modified Griffiths scale,2 where 0 = none, 1 to 3 = mild, 4 to 6 = moderate, 7 to 9 = severe) full-face hyperpigmentation, including melasma. Hyperpigmentation and melasma must present at equal severity and size on each facial side. * Willing to maintain visit 1/baseline condition of eyebrows and eyelashes (do not noticeably change brow/lash appearance) during the study. * Willing to provide written informed consent and able to read, speak, write, and understand English. * Willing to sign a photography release. * Having not had any facial treatments in the past 6 months and are willing to withhold all facial treatments during the course of the study including facials, facial peels, photo facials, laser treatments, dermabrasion, botulinum toxin (Botox®), injectable filler treatments, intense pulsed light (IPL), acid treatments, tightening treatments, facial plastic surgery, or any other treatment administered by a physician or skin care professional designed to improve the appearance or firmness of facial skin. Waxing and threading are allowed but not facial laser hair removal. Exclusion Criteria: * Having been diagnosed with known allergies to skin care products. * Having a known reactivity to tranexamic acid, niacinamide, sunflower seed, coconut, rosemary, barley, goji, sandalwood, licorice root, radish root, beeswax, yeast, ascorbic acid, tetrahexyldecyl ascorbate, and/or any of the ingredients in the study products. * Breastfeeding, pregnant, or planning to become pregnant during the study according to subject self-report. * Having a history of skin cancer within the past 5 years. * Currently taking oral or topical prescription medications for melasma such as Triluma, compounded hydroquinone, retinoids, and tranexamic acid. * Currently using oral or topical prescription medications for acne such as doxycycline, minocycline, clindamycin, bactrim, tetracycline, erythromycin, vibramycin, azelaic acid, benzoyl peroxide, Dapsone, or sodium sulfacetamide.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dark spots are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Revision Skincare
Irving, Texas, 75063, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Apple peptides may speed skin healing after cosmetic procedures
- Can stem cell exosomes fade melasma patches?
- Can seaweed microspicules turn back the clock on aging skin?
- A new gel aims to fade dark Spots—Will it deliver a brighter complexion?
- Can a new laser erase acne scars without harming darker skin?
- Can a simple pill make melasma creams work better?